# Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia

> **NCT01360164** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Beike Bio-Technology Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Hereditary Ataxia

## Interventions

- **BIOLOGICAL:** human umbilical cord mesenchymal stem cells

## Key facts

- **NCT ID:** NCT01360164
- **Lead sponsor:** Shenzhen Beike Bio-Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-11-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360164, "Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01360164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*